[Treatment with antiangiogenic drugs]

Abstract

Antiangiogenesis therapy with bevacizumab demonstrated better response rate, progression free survival and overall survival in various kind of tumors including colon, breast, lung and renal cancer. It mainly potentiates antitumor activity of cytotoxic drugs. Problems remain in high cost of antibody and adverse events such as hypertension and bleeding. Small molecules of VEGF-TKI could not show survival benefit by many randomized controlled trials except for renal and hepatic cancer.